Browse result page of B3Pdb

The total number entries retrieved from this search are 9, scroll left/right for detailed information.

B3pdbID	PEPTIDE NAME	PEPTIDE SEQUENCE (1-letter)	PEPTIDE SEQUENCE (3-letter)	N-TERMINAL MODIFICATION	C-TERMINAL MODIFICATION	CHEMICAL MODIFICATION	PEPTIDE LENGTH	PEPTIDE CONFORMATION	PEPTIDE NATURE	SOURCE/ORIGIN OF PEPTIDE	SMILES	CELL LINE	In vitro CONCENTRATION	In vitro METHOD	In vitro RESULT	ANIMAL MODEL	In vivo CONCENTRATION	In vivo MODE OF DELIVERY	In vivo METHOD	In vivo RESULT	ACTION	TRANSPORT TYPE	SUBCELLULAR LOCALISATION	COMBINATION	PHYSICAL CONDITION	RESPONSE	RESULT	LABEL	PMID
B3pdbIDb3pdb_0006	PEPTIDE NAMENR2B9c	PEPTIDE SEQUENCE (1-letter)KLSSIESDV	PEPTIDE SEQUENCE (3-letter)LysLeuSerSerIleGluSerAspVal	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH9	PEPTIDE CONFORMATIONNA	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)O	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELRat	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal	In vivo METHODHPLC-MS/MS	In vivo RESULTNR2B9c-WGA-NPs are able to bypass the BBB and effectively transport NR2B9c into the brain and neuron	ACTIONIt can protect neurons against excitotoxicity, reduce ischemic brain injury and ameliorate neurologi	TRANSPORT TYPEtranscytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONNR2B9c is combined with WGA-modified nanoparticles	PHYSICAL CONDITIONischemic stroke	RESPONSENA	RESULTNA	LABELNA	PMID 30428334
B3pdbIDb3pdb_0042	PEPTIDE NAMEMVIIA (ziconotide)	PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKC	PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCys	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH25	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)O	CELL LINEHEK293 cells	In vitro CONCENTRATIONNA	In vitro METHODAcetic Acid-Induced WRITHING test	In vitro RESULTInhibitory activity toward N-type calcium channels.	ANIMAL MODELKunming mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal and Intervenous	In vivo METHODTremor Symptom Test	In vivo RESULTIt induces tremor symptoms	ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi	TRANSPORT TYPEReceptor-mediated transcytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONComined with TAT-protein	PHYSICAL CONDITIONNA	RESPONSEMIC	RESULT0.0436 micromolar	LABELNA	PMID 31083641
B3pdbIDb3pdb_0043	PEPTIDE NAMEMVIIA-a	PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKCYGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysTyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH36	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O	CELL LINEHEK293 cells	In vitro CONCENTRATIONNA	In vitro METHODAcetic Acid-Induced WRITHING test	In vitro RESULTInhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i	ANIMAL MODELKunming mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal and Intervenous	In vivo METHODTremor Symptom Test	In vivo RESULTIt induces tremor symptoms	ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi	TRANSPORT TYPEReceptor-mediated transcytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONCombined with TAT protein	PHYSICAL CONDITIONNA	RESPONSEMIC	RESULT0.413 micromolar	LABELNA	PMID 31083641
B3pdbIDb3pdb_0044	PEPTIDE NAMEMVIIA-b	PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKCGYGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyTyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH37	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O	CELL LINEHEK293 cells	In vitro CONCENTRATIONNA	In vitro METHODAcetic Acid-Induced WRITHING test	In vitro RESULTInhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i	ANIMAL MODELKunming mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal and Intervenous	In vivo METHODTremor Symptom Test	In vivo RESULTIt induces tremor symptoms	ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi	TRANSPORT TYPEReceptor-mediated transcytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONCombined with TAT protein	PHYSICAL CONDITIONNA	RESPONSEMIC	RESULT0.379 micromolar	LABELNA	PMID 31083641
B3pdbIDb3pdb_0045	PEPTIDE NAMEMVIIA-c	PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKCGGYGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyGlyTyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH38	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O	CELL LINEHEK293 cells	In vitro CONCENTRATIONNA	In vitro METHODAcetic Acid-Induced WRITHING test	In vitro RESULTInhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i	ANIMAL MODELKunming mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal and Intervenous	In vivo METHODTremor Symptom Test	In vivo RESULTIi did not induce tremor symptoms.	ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi	TRANSPORT TYPEReceptor-mediated transcytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONCombined with TAT protein	PHYSICAL CONDITIONNA	RESPONSEMIC	RESULT0.237 micromolar	LABELNA	PMID 31083641
B3pdbIDb3pdb_0046	PEPTIDE NAMEMVIIA-d	PEPTIDE SEQUENCE (1-letter)CKGKGAKCSRLMYDCCTGSCRSGKCGGGYGRKKRRQRRR	PEPTIDE SEQUENCE (3-letter)CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCysGlyGlyGlyTyrGlyArgLysLysArgArgGlnArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION TAT-transducing domain was fused at C-terminal	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH39	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDENA	SMILESN[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O	CELL LINEHEK293 cells	In vitro CONCENTRATIONNA	In vitro METHODAcetic Acid-Induced WRITHING test	In vitro RESULTInhibitory activity toward N-type calcium channels, albeit with a slightly reduced endothelialcacy i	ANIMAL MODELKunming mice	In vivo CONCENTRATIONNA	In vivo MODE OF DELIVERYIntranasal and Intervenous	In vivo METHODTremor Symptom Test	In vivo RESULTIt induces tremor symptoms	ACTIONIt showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi	TRANSPORT TYPEReceptor-mediated transcytosis	SUBCELLULAR LOCALISATIONNA	COMBINATIONCombined with TAT protein	PHYSICAL CONDITIONNA	RESPONSEMIC	RESULT0.345 micromolar	LABELNA	PMID 31083641
B3pdbIDb3pdb_0152	PEPTIDE NAMEMPEG-PCL-Tat	PEPTIDE SEQUENCE (1-letter)NA	PEPTIDE SEQUENCE (3-letter)NA	N-TERMINAL MODIFICATIONAddition of MPEG and ploygalactolactone	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONAddition of MPEG and PCL	PEPTIDE LENGTHNA	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELAdult Sprague-Dawley rats	In vivo CONCENTRATION10 microliter	In vivo MODE OF DELIVERYIntranasal	In vivo METHODFluoroscent screening by FITC labbled peptide maass in brain tissue	In vivo RESULT2.5% fluoroscence observed in brain tissue	ACTIONNA	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONNA	PHYSICAL CONDITIONNA	RESPONSENA	RESULTNA	LABELNA	PMID 23992922
B3pdbIDb3pdb_0233	PEPTIDE NAMEProtamine	PEPTIDE SEQUENCE (1-letter)VSRRRRRRGGRRRR	PEPTIDE SEQUENCE (3-letter)ValSerArgArgArgArgArgArgGlyGlyArgArgArgArg	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH13	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURECationic	SOURCE/ORIGIN OF PEPTIDEDerived from protamine	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELBALB/c mice	In vivo CONCENTRATION10 microliter per nostril	In vivo MODE OF DELIVERYIntranasal	In vivo METHODIn vivo imaging	In vivo RESULTPeptide + BSA combination deleiveerd in brain olfactory bulb and littlebit in cerebral	ACTIONpeptide can deliver drug into brain tissue	TRANSPORT TYPENA	SUBCELLULAR LOCALISATIONNA	COMBINATIONPeptide+BSA	PHYSICAL CONDITIONNA	RESPONSENA	RESULTNA	LABELNA	PMID 27471676
B3pdbIDb3pdb_1209	PEPTIDE NAMEPenetratin	PEPTIDE SEQUENCE (1-letter)RQIKIWFQNRRMKWKK	PEPTIDE SEQUENCE (3-letter)NA	N-TERMINAL MODIFICATIONNA	C-TERMINAL MODIFICATION NA	CHEMICAL MODIFICATIONNA	PEPTIDE LENGTH16	PEPTIDE CONFORMATIONLinear	PEPTIDE NATURENA	SOURCE/ORIGIN OF PEPTIDEChemically synthesized	SMILESNA	CELL LINENA	In vitro CONCENTRATIONNA	In vitro METHODNA	In vitro RESULTNA	ANIMAL MODELMale Sprague-Dawley rats	In vivo CONCENTRATION2.0 mM	In vivo MODE OF DELIVERYIntranasal	In vivo METHODELISA	In vivo RESULTL-penetratin increased the systemic absorption of leptin after intranasal administration.	ACTIONThe intranasal coadministration with L-penetratin could deliver leptin to the brain and in particula	TRANSPORT TYPEPermeability	SUBCELLULAR LOCALISATIONHypothalamus	COMBINATIONCombined with leptin	PHYSICAL CONDITIONObesity	RESPONSENA	RESULTThe intranasal coadministration with L-penetratin has a potential to deliver leptin into the therape	LABELNA	PMID 31926192